IGF2 supports glioblastoma growth and immune evasion through a combination of tumor cell-intrinsic and -extrinsic mechanisms
mBT0309 is a valuable syngeneic model for studying immunosuppression and therapeutic resistance in GBM. IGF2 offers promise as a valuable therapeutic target to combat tumor growth and immunosuppression in GBM patients.
Authors
- Mathieu Meode (ORCID: https://orcid.org/0009-0002-5073-3651)
- H. Artee Luchman (ORCID: https://orcid.org/0000-0002-6663-9929)
- Smriti Kala (ORCID: https://orcid.org/0000-0002-7147-0291)
- Shannon Snelling (ORCID: https://orcid.org/0000-0002-2504-235X)
- Rozina Hassam
- Samir Assaf
- Orsolya Cseh
- Samuel Weiss
- J. Gregory Cairncross (ORCID: https://orcid.org/0000-0002-5169-5039)
- Kyle Heemskerk
- Jennifer A. Chan (ORCID: https://orcid.org/0000-0001-9798-1551)
- Franz J. Zemp (ORCID: https://orcid.org/0000-0002-8845-3535)
- Reza Mirzaei (ORCID: https://orcid.org/0000-0002-2393-2770)
- V. Wee Yong (ORCID: https://orcid.org/0000-0002-2600-3563)
- James M. Pemberton (ORCID: https://orcid.org/0000-0001-8386-1081)
- Xiaoguang Hao (ORCID: https://orcid.org/0000-0003-2695-0111)
- Peter Forsyth (ORCID: https://orcid.org/0000-0001-7841-7891)
Institutions
- University of Alberta (CA)
- University of Calgary (CA)
- Moffitt Cancer Center (US)
- Standard Bio (Norway) (NO)
- Canadian Standards Association (CA)
- Alberta Cancer Foundation (CA)
- Alberta Bone and Joint Health Institute (CA)
Publication Details
- Journal
- Neuro-Oncology Advances
- Published
- 2025-10-15
- DOI
- https://doi.org/10.1093/noajnl/vdaf226
- Primary Topic
- Cancer, Hypoxia, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- University of Calgary
- Canadian Institutes of Health Research